Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial -

Efficacy and safety of fosaprepitant for the prevention of nausea and emesis during 5 weeks of chemoradiotherapy for cervical cancer (the GAND-emesis study): a multinational, randomised, placebo-controlled, double-blind, phase 3 trial
Information type: Randomised controlled trials
Source: The Lancet Oncology
Specialities: Cancers
Summary
In this RCT (n=246) the cumulative risk for emesis was lower with fosaprepitant with palonosetron and dexamethasone (P+D) compared with placebo and P+D (subhazard ratio = 0.58, 95%CI= 0.39-0.87, p=0.008). Patients were receiving treatment with weekly cisplatin chemotherapy.
UKMi comment
A related commentary discusses the implications of this research.
Related links: Related commentary